Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
LeMaitre Vascular is a niche medical device manufacturer specializing in peripheral vascular surgery products, including valvulotomes, carotid shunts, vascular grafts, and surgical instruments used in arterial reconstruction procedures. The company operates a direct sales model in major markets (US, Germany, France, UK) and distributor networks in 100+ countries, competing through specialized product portfolio rather than scale. Stock performance is driven by procedure volumes in vascular surgery, new product adoption rates, and international expansion success.
LeMaitre generates revenue through direct sales of proprietary and acquired peripheral vascular devices to hospitals and surgical centers. The company maintains 68.6% gross margins through specialized product positioning in procedures with limited alternatives, avoiding commodity competition. Pricing power stems from surgeon preference for proven devices in critical arterial procedures where switching costs are high due to training requirements and clinical familiarity. The business model emphasizes acquiring complementary product lines (historical M&A strategy) and expanding geographic reach through direct sales force investments in developed markets.
US vascular surgery procedure volumes, particularly carotid endarterectomy and peripheral bypass procedures
International revenue growth rates, especially in European direct markets (Germany, France, UK) and emerging distributor territories
New product launch success and market share gains in existing device categories
Acquisition announcements and integration execution of tuck-in product line acquisitions
Gross margin trends reflecting product mix shifts and manufacturing efficiency improvements
Reimbursement pressure from Medicare and private insurers reducing hospital budgets for vascular devices, particularly as value-based care models emphasize cost containment over fee-for-service volumes
Technological shift toward endovascular procedures (stents, angioplasty) reducing demand for open surgical devices in peripheral vascular interventions, as minimally invasive techniques gain clinical acceptance
Regulatory burden from FDA and international agencies increasing compliance costs and lengthening product approval timelines for small-cap medtech companies without scale advantages
Large diversified medtech competitors (Medtronic, BD, Teleflex) entering niche vascular markets with superior sales force scale and cross-selling capabilities across broader product portfolios
Pricing pressure from hospital group purchasing organizations (GPOs) consolidating procurement and demanding volume discounts that erode margins for specialized device manufacturers
Surgeon preference fragmentation as younger vascular surgeons trained on competing devices reduce LeMaitre's historical installed base advantage
Acquisition integration risk if purchased product lines underperform revenue expectations or require higher-than-anticipated investment in sales infrastructure and regulatory compliance
Foreign exchange exposure from international operations (estimated 30-40% of revenue) creating earnings volatility, particularly EUR/USD and GBP/USD fluctuations impacting European direct sales
low - Peripheral vascular procedures are medically necessary interventions for arterial disease, driven by patient demographics (aging population) and clinical need rather than discretionary spending. However, elective procedure scheduling can experience modest delays during severe economic downturns when patients defer non-emergency surgeries due to insurance concerns or hospital capacity constraints. The company's revenue showed resilience during past recessions, with procedure volumes more correlated to Medicare enrollment growth than GDP fluctuations.
Rising interest rates have moderate negative impact through two channels: (1) higher cost of capital for potential acquisitions, which are central to LeMaitre's growth strategy and typically financed with debt, and (2) valuation multiple compression for high-growth medtech stocks as investors rotate toward higher-yielding fixed income. The company's 0.49 debt/equity ratio provides flexibility, but acquisition financing becomes more expensive in rising rate environments. Hospital capital budgets may tighten with higher borrowing costs, though impact on consumable device purchases is minimal.
Minimal direct credit exposure. Customers are primarily hospitals and surgical centers with stable payment histories, and accounts receivable risk is low given healthcare reimbursement structures. The company's 13.58 current ratio indicates strong liquidity with no near-term refinancing risk. Credit conditions affect acquisition financing availability and pricing, but the balance sheet can support organic growth without external capital.
growth - The stock attracts growth-oriented investors seeking exposure to niche medical device markets with double-digit revenue growth potential (13.6% TTM) and margin expansion opportunities. The 8.5x price/sales ratio reflects premium valuation for consistent organic growth and M&A-driven product portfolio expansion. Limited dividend yield (not material) indicates reinvestment focus. Investors value the company's specialized market position and international expansion runway, accepting higher valuation multiples for sustainable growth in aging demographics-driven end markets.
moderate-to-high - Small-cap healthcare stocks with $2.1B market cap typically exhibit elevated volatility relative to large-cap medtech peers. The -12.2% one-year return and -5.0% six-month performance reflect sensitivity to medtech sector rotation and interest rate concerns. Quarterly earnings can drive significant price swings given limited analyst coverage and institutional ownership concentration. Beta likely ranges 1.1-1.3x, with volatility amplified by acquisition announcements and FDA approval outcomes for new products.
